These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 18638223

  • 1. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
    Yip L, Harrison S, Foley P.
    Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H, Groupe Français de Recherche sur le Psoriasis.
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [Abstract] [Full Text] [Related]

  • 3. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G, Sánchez-Carazo JL, Mahiques L, Oliver V.
    Dermatology; 2008 Oct; 216(4):312-6. PubMed ID: 18230978
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 6. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 7. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 8. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A, García-Donoso C, Martinez-Morán C, Hernández-Núñez A, Borbujo J.
    Dermatol Online J; 2010 Jun 15; 16(6):15. PubMed ID: 20579470
    [Abstract] [Full Text] [Related]

  • 9. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL, de Groot M, Bos JD, Spuls PI.
    Br J Dermatol; 2009 Oct 15; 161(4):948-51. PubMed ID: 19663876
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A, Esposito M, Costanzo A, Chimenti S.
    Am J Clin Dermatol; 2009 Oct 15; 10(5):319-24. PubMed ID: 19658444
    [Abstract] [Full Text] [Related]

  • 11. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM, Saini R.
    Cutis; 2003 Jan 15; 71(1):25-9. PubMed ID: 12553627
    [Abstract] [Full Text] [Related]

  • 12. [Biologic therapies in the treatment of psoriasis].
    Farhi D, Dupin N.
    Presse Med; 2009 May 15; 38(5):832-43. PubMed ID: 19282134
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.
    Am J Clin Dermatol; 2013 Aug 15; 14(4):315-26. PubMed ID: 23696234
    [Abstract] [Full Text] [Related]

  • 14. Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.
    Kramer JM, Turner JE.
    Am J Clin Dermatol; 2009 Aug 15; 10(2):134-40. PubMed ID: 19222255
    [Abstract] [Full Text] [Related]

  • 15. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
    van Lingen RG, Körver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM.
    Br J Dermatol; 2008 Jul 15; 159(1):91-6. PubMed ID: 18476954
    [Abstract] [Full Text] [Related]

  • 16. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G, Errichetti E.
    BioDrugs; 2015 Apr 15; 29(2):91-101. PubMed ID: 25752640
    [Abstract] [Full Text] [Related]

  • 17. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies.
    Prignano F, Ricceri F, Pescitelli L, Buggiani G, Troiano M, Zanieri F, Rossari S, Lotti T.
    Curr Med Res Opin; 2009 Sep 15; 25(9):2311-6. PubMed ID: 19635043
    [Abstract] [Full Text] [Related]

  • 18. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R.
    J Drugs Dermatol; 2011 Apr 15; 10(4):396-402. PubMed ID: 21455550
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S.
    Dermatology; 2009 Apr 15; 219(1):48-53. PubMed ID: 19372639
    [Abstract] [Full Text] [Related]

  • 20. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr 15; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.